|
Parameters
|
Dapagliflozin group
|
Metformin group
|
P value
|
|---|
|
Urinary 8-OHdG/creatinine (ng/mg Cre)
|
|
Baseline
|
4.3 ± 1.7 (13)
|
4.4 ± 2.0 (17)
|
0.88
|
|
Week 16
|
4.1 ± 1.1 (13)
|
5.7 ± 2.4 (17)
|
0.021
|
|
Change
|
−0.2 ± 1.6 (13)
|
1.3 ± 2.3 (17)
|
0.042
|
|
P value within group
|
0.66
|
0.031
| |
|
Red blood cell (×104/μL)
|
|
Baseline
|
485.6 ± 32.2 (13)
|
463.5 ± 41.4 (16)
|
0.12
|
|
Week 16
|
507.9 ± 34.8 (12)
|
453.4 ± 30.9 (15)
|
<0.001
|
|
Change
|
21.3 ± 13.2 (12)
|
−14.7 ± 18.1 (15)
|
<0.001
|
|
P value within group
|
<0.001
|
0.007
| |
|
Hemoglobin (g/dL)
|
|
Baseline
|
14.9 ± 0.8 (13)
|
14.0 ± 1.3 (16)
|
0.036
|
|
Week 16
|
15.6 ± 0.7 (12)
|
14.0 ± 1.9 (15)
|
0.008
|
|
Change
|
0.7 ± 0.4 (12)
|
−0.1 ± 1.3 (15)
|
0.030
|
|
P value within group
|
<0.001
|
0.67
| |
|
Hematocrit (%)
|
|
Baseline
|
44.1 ± 2.3 (13)
|
41.7 ± 3.7 (16)
|
0.048
|
|
Week 16
|
46.1 ± 2.0 (12)
|
40.7 ± 3.0 (15)
|
<0.001
|
|
Change
|
2.0 ± 1.3 (12)
|
−1.4 ± 1.7 (15)
|
<0.001
|
|
P value within group
|
<0.001
|
0.007
| |
|
Uric acid (mg/dL)
|
|
Baseline
|
5.9 ± 0.8 (13)
|
5.0 ± 0.9 (17)
|
0.012
|
|
Week 16
|
5.2 ± 0.6 (12)
|
5.3 ± 1.0 (17)
|
0.74
|
|
Change
|
−0.7 ± 0.7 (12)
|
0.3 ± 0.5 (17)
|
<0.001
|
|
P value within group
|
0.007
|
0.041
| |
- Data are mean ± standard deviation (n). P values show results for comparisons between groups by t test or Wilcoxon rank sum test. P values within groups are results of paired t test or Wilcoxon signed rank test
